The Effect of 3-Month Growth Hormone Administration and 12-Month Follow-Up Duration among Heart Failure Patients Four Weeks after Myocardial Infarction: A Randomized Double-Blinded Clinical Trial

Table 1

Characteristics of study participants across different categories of intervention or control group at baseline and 12 months after study initiation.

			GH group ()	Placebo group ()	value
Baseline	Age (years)				0.21
	BMI (kg/m^2)				0.64
	Education level (≥diploma)		87.5	100	0.93
	Occupation status	Employee	62.5	50	0.48
		Retired	37.5	50
	Blood pressure (mmHg)	Systolic			0.09
		Diastolic
	Hemoglobin (g/dl)				0.51
	Cholesterol (mg/dl)				0.32
	Triglyceride (mg/dl)				0.59
	LDL-C (mg/dl)				0.66
	HDL-C (mg/dl)				0.18
	eGFR (ml/min/1.73m^2)				0.88
	Medication usage (%)	ACEI/ARB	100	100	0.18
		β-Blocker	100	100
		COX-inhibitors	100	100
		HMG COA reductase inhibitor	100	100
		Thienopyridines	100	100
After 12 months	Age (years)				0.13
	Weight (kg)				0.38
	BMI (kg/m^2)				0.28
	Blood pressure (mmHg)	Systolic			0.75
		Diastolic			0.65
	Hemoglobin (g/dl)				0.85
	Cholesterol (mg/dl)				0.66
	Triglyceride (mg/dl)				0.75
	LDL-C (mg/dl)				0.38
	HDL-C (mg/dl)				0.59
	eGFR (ml/min/1.73m^2)				0.56
	Medication usage (%)	ACEI/ARB	100	100	1.00
		β-Blocker	100	100
		COX-inhibitors	100	100
		HMG COA reductase inhibitor	100	100
		Thienopyridines	100	100

GH: growth hormone; BMI: body mass index; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; eGFR: estimated glomerular filtration rate; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; COX-inhibitor: cyclooxygenase inhibitor; HMG-CoA: 3-hydroxy-3-methyl-glutaryl-CoA.